Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof
US 12,187,707 In forceTerm ends Apr 18, 2039 · From the USPTO record
20-year base term ends Jun 15, 2038
Jun 15, 2018
Apr 18, 2039
Jan 7, 2025
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 15, 2018, when the earliest non-provisional application in its chain was filed (this one was filed Nov 12, 2021); a parent in its chain could not be resolved (the next row) | Jun 15, 2038 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +307 days, USPTO patent term adjustment record | Apr 18, 2039 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Apr 18, 2039 | From the USPTO record |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.